businesspress24.com - Immunotec Reports Issuance of Options
 

Immunotec Reports Issuance of Options

ID: 1387104

(firmenpresse) - VAUDREUIL-DORION, QUEBEC -- (Marketwired) -- 09/22/15 -- Immunotec Inc. (TSX VENTURE: IMM), a direct-to-consumer company and a leader in the nutritional industry (the "Company" or "Immunotec"), today announced that pursuant to the Immunotec Stock Option Plan, an officer was granted options entitling him to acquire up to 100,000 common shares of the Company (the "Shares"). The exercise price of such options was established at $0.265, which is the closing price of the Shares on the TSX Venture Exchange the day before their issuance. These options will vest over a three-year period, with one-third (1/3) which will vest on each of the first, second and third anniversaries of the date of the grant. Each option is exercisable, once vested, for a period of five years from the date of grant.

About Immunotec Inc.

Immunotec is a Canadian-based Company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S. and Mexico. The Company offers an extensive family of nutritional products targeting health, wellness, weight management, as well as energy and performance. The Immunocal family of products is supported by over 40 published articles and supporting science in medical and scientific literature.

Please visit us at for additional information.

The Company files its continuous disclosure documents on the SEDAR database at and on the Company''s website at . The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Immunotec Inc.
Patrick Montpetit CPA, CA, CF
Vice-President and Chief Financial Officer
(450) 510-4527




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Therapeutic Solutions International Develops Cytokine Based Diagnostic Test for Preterm Labor and Complications of Pregnancy
Nobilis Expands Hospital Network to Phoenix
Bereitgestellt von Benutzer: Marketwired
Datum: 22.09.2015 - 06:55 Uhr
Sprache: Deutsch
News-ID 1387104
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

VAUDREUIL-DORION, QUEBEC


Phone:

Kategorie:

Health & Nutrition


Anmerkungen:


Diese Pressemitteilung wurde bisher 171 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Immunotec Reports Issuance of Options
"
steht unter der journalistisch-redaktionellen Verantwortung von

Immunotec Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Immunotec Inc.



 

Who is online

All members: 10 591
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 393


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.